The earnings call highlighted strong revenue growth and sustained profitability, driven by the impressive performance of ELEVIDYS and the PMO franchise. Despite the setback of discontinuing the SRP-5051 program, Sarepta's financial health remains robust, and confidence in future performance is high.

Company Guidance

During the Sarepta Therapeutics earnings call for Q3 2024, the company provided detailed guidance regarding their financial performance and strategic plans. They reported a total net product revenue of approximately $430 million, marking a 39% increase compared to the same quarter in the previous year. Specifically, ELEVIDYS net product revenue reached $181 million, significantly exceeding previous guidance and analyst consensus. The PMO franchise, including EXONDYS 51, VYONDYS 53, and AMONDYS 45, contributed approximately $249 million. Sarepta expressed confidence in meeting Q4 expectations and reiterated their guidance for 2025, projecting $3 billion in revenue with two-thirds from ELEVIDYS. Additionally, they highlighted advancements in their R&D pipeline, including the decision to discontinue the SRP-5051 development program and progress in late-stage clinical trials for their limb-girdle muscular dystrophy programs. The company anticipates being sustainably profitable on a GAAP and non-GAAP basis and turning cash flow positive early in 2025.

Strong Q3 Revenue Growth

Total net product revenue reported at about $430 million, growing at 39% year-over-year. ELEVIDYS net product revenue reached $181 million, with a 50% increase compared to the prior quarter.

ELEVIDYS Performance Exceeds Expectations

ELEVIDYS revenue including royalties from Roche's ex-U.S. performance achieved $190.5 million, exceeding prior guidance and analyst consensus. The product is seeing strong demand from both ambulant and non-ambulant populations.

PMO Franchise Resilience

PMO sales comprising EXONDYS 51, VYONDYS 53, and AMONDYS 45 achieved approximately $249 million, exceeding analyst consensus, with EXONDYS 51 leading with $140.7 million.

Sustainable Profitability

Reported GAAP net income of $33.6 million and non-GAAP net income of $67 million, with expectations to be sustainably profitable and cash flow positive early in 2025.

---

Sarepta Therapeutics (SRPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SRPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 26, 2025	2024 (Q4)	1.92 / -	0.47	―	―	―
Nov 06, 2024	2024 (Q3)	-0.07 / 0.34	-0.46	173.91% (+0.80)	―
Aug 07, 2024	2024 (Q2)	-0.13 / 0.07	-0.27	125.93% (+0.34)	―
May 01, 2024	2024 (Q1)	0.01 / 0.37	-5.86	106.31% (+6.23)	―
Feb 28, 2024	2023 (Q4)	0.07 / 0.47	-1.24	137.90% (+1.71)	―
Nov 01, 2023	2023 (Q3)	-1.22 / -0.46	-2.94	84.35% (+2.48)	―
Aug 02, 2023	2023 (Q2)	-1.78 / -0.27	-2.65	89.81% (+2.38)	―
May 02, 2023	2023 (Q1)	-1.29 / -5.86	-1.2	-388.33% (-4.66)	―
Feb 28, 2023	2022 (Q4)	-1.47 / -1.24	-1.42	12.68% (+0.18)	―
Nov 02, 2022	2022 (Q3)	-1.22 / -2.94	-0.6	-390.00% (-2.34)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

SRPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2024	$127.97	$120.42	-5.90%
Aug 07, 2024	$140.06	$136.40	-2.61%
May 01, 2024	$130.90	$130.63	-0.21%
Feb 28, 2024	$137.50	$127.90	-6.98%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---